https://www.selleckchem.com/pr....oducts/cct128930.htm
Combination therapy using palbociclib with Bay11-7082 was significantly more effective in hepatoblastoma and HCC treatment than single administration. Moreover, blockade of IKK-NF-κB or AKT pathway enhanced effects of palbociclib on RB1-intact K-Ras mutated lung and colon cancers. In conclusion, CDK4/6 inhibitors have a potential to treat a wide variety of RB1-intact cancers including HCC when combined with an appropriate kinase inhibitor.The aim of the present study was to design a delivery system of curcumin (CU) loaded solid lipid
Like
Comment
Share
